CN113646310A - 结晶性的嘧啶基-3,8-二氮杂双环[3.2.1]辛烷基甲酮化合物及其用途 - Google Patents

结晶性的嘧啶基-3,8-二氮杂双环[3.2.1]辛烷基甲酮化合物及其用途 Download PDF

Info

Publication number
CN113646310A
CN113646310A CN202080028910.4A CN202080028910A CN113646310A CN 113646310 A CN113646310 A CN 113646310A CN 202080028910 A CN202080028910 A CN 202080028910A CN 113646310 A CN113646310 A CN 113646310A
Authority
CN
China
Prior art keywords
crystalline form
crystalline
diazabicyclo
pyrazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080028910.4A
Other languages
English (en)
Chinese (zh)
Inventor
X·杨
A·P·S·萨米尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN113646310A publication Critical patent/CN113646310A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
CN202080028910.4A 2019-02-15 2020-02-12 结晶性的嘧啶基-3,8-二氮杂双环[3.2.1]辛烷基甲酮化合物及其用途 Pending CN113646310A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806180P 2019-02-15 2019-02-15
US62/806180 2019-02-15
PCT/IB2020/051128 WO2020165788A1 (en) 2019-02-15 2020-02-12 Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof

Publications (1)

Publication Number Publication Date
CN113646310A true CN113646310A (zh) 2021-11-12

Family

ID=69726639

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080028910.4A Pending CN113646310A (zh) 2019-02-15 2020-02-12 结晶性的嘧啶基-3,8-二氮杂双环[3.2.1]辛烷基甲酮化合物及其用途

Country Status (15)

Country Link
US (2) US12312358B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924355B1 (cg-RX-API-DMAC7.html)
JP (1) JP7561497B2 (cg-RX-API-DMAC7.html)
KR (2) KR102820235B1 (cg-RX-API-DMAC7.html)
CN (1) CN113646310A (cg-RX-API-DMAC7.html)
AR (1) AR118099A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020222083B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130034C (cg-RX-API-DMAC7.html)
ES (1) ES3065864T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021009761A (cg-RX-API-DMAC7.html)
SG (1) SG11202108863WA (cg-RX-API-DMAC7.html)
TW (1) TWI820301B (cg-RX-API-DMAC7.html)
WO (1) WO2020165788A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106815B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102820235B1 (ko) * 2019-02-15 2025-06-16 화이자 인코포레이티드 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
US12673955B2 (en) 2020-06-09 2026-07-07 Crystal Pharmatech Co., Ltd. Crystal form of p-toluenesulfonate salt of diazabicyclic compound and preparation method therefor
CN114835717A (zh) * 2021-02-01 2022-08-02 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074867A (zh) * 2014-08-21 2017-08-18 辉瑞公司 作为jak抑制剂的氨基嘧啶基化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5023556A (en) 1990-02-02 1991-06-11 Conax Florida Corporation Sensor circuit response to different fluid conductivities and having time delay feature
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
KR20260080448A (ko) * 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
KR102820235B1 (ko) * 2019-02-15 2025-06-16 화이자 인코포레이티드 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074867A (zh) * 2014-08-21 2017-08-18 辉瑞公司 作为jak抑制剂的氨基嘧啶基化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREW FENSOME等: "Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)‑2, 2-Difluorocyclopropyl)((1R, 5S)‑3-(2-((1- methyl‑1H‑pyrazol-4-yl)amino)pyrimidin-4-yl)-3, 8- diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)", J. MED. CHEM., vol. 61, no. 19, pages 8597 - 8612 *
STEPHEN T. WROBLESKI等: "Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165", J. MED. CHEM., vol. 62, no. 20, pages 8973 *

Also Published As

Publication number Publication date
TWI820301B (zh) 2023-11-01
CA3130034C (en) 2023-12-19
US20220144846A1 (en) 2022-05-12
ZA202106815B (en) 2026-03-25
JP2020138960A (ja) 2020-09-03
EP3924355B1 (en) 2025-12-31
KR102820235B1 (ko) 2025-06-16
SG11202108863WA (en) 2021-09-29
AU2020222083A1 (en) 2021-09-02
EP3924355A1 (en) 2021-12-22
EP3924355C0 (en) 2025-12-31
JP7561497B2 (ja) 2024-10-04
KR20240116855A (ko) 2024-07-30
ES3065864T3 (en) 2026-05-08
CA3130034A1 (en) 2020-08-20
AU2020222083B2 (en) 2022-11-17
AR118099A1 (es) 2021-09-15
US20250282789A1 (en) 2025-09-11
US12312358B2 (en) 2025-05-27
TW202045511A (zh) 2020-12-16
MX2021009761A (es) 2021-12-15
BR112021015951A2 (pt) 2021-10-05
KR20210114470A (ko) 2021-09-23
WO2020165788A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
US20250282789A1 (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
EP3817810B1 (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
US20190040054A1 (en) Solid state forms of dasatinib and processes for their preparation
HK40059389A (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1] octanylmethanone compound and use thereof
RU2803145C2 (ru) Кристаллический пиримидинил-3,8-диазабицикло[3.2.1]октанилметанон и его применение
TWI873326B (zh) (1R,3R)-3-(氰甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡-4-基)-1H-吡唑-1-基)環丁烷-1-甲腈之結晶型及其製備方法與用途
HK40088917B (en) Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
HK40088917A (en) Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
HK40047992A (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059389

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20211112

RJ01 Rejection of invention patent application after publication